Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,669   2.87  Index Moved Up 0.17%
JNJ PFE NVS SNY Small Value Emerging Markets Health Management Basic Utilities 
United States GSPC USD ...  |  Check Insiders


Processing
Collecting data for NVS

Novartis quote and profile

 
 Companies |  Insiders  | Dashboard  
     
74.63
  
STOCK
0.47  Macroaxis: 0.63 Up   0.63%  
Year To Date
51.275.67
Last 1 Month(s)
72.4875.5
Trading Day 
73.7674.82
May 22 2013 

Diversification Suggestion

Use Novartis to enhance returns of your portfolios. The stock experiences moderate upward volatility
Analyze Novartis AG Trend or Check current 30 days Novartis correlation with market (S&P 500)
1 Month Beta 0.43  
Highest Price:  
Lowest Price:  
75.5  
72.48  
May 15 2013 
April 24 2013 
As returns on market increase, Novartis returns are expected to increase less than the market. However during bear market, the loss on holding Novartis will be expected to be smaller as well.
Novartis AG Small BetaNovartis AG Beta Legend
NVS United States NYSE
Novartis AG
Healthcare
Drug Manufacturers - Major
Benchmark S&P 500
http://www.novartis.com
Contact Number: 41 61 324 11 11
Currency: USD - US Dollar
Traded on New York Stock Exchange
    
Current Valuation193.32 B
Shares Outstanding2.44 B
Number of Shares Shorted3.2 M
Revenue57.8 B
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 thisGreen NVS NVS agains markets  0.63 % Macroaxis: 0.63 Moved Up  
 
 United States SP 500   0.17 % Macroaxis: 0.17 Moved Up  
 
 United States NYSE   0.11 % Macroaxis: 0.11 Moved Up  
 
 United States Russel   0.08 % Macroaxis: 0.08 Moved Up  
 
Compare to Competition Get Alpha   Get Advice

Novartis Leadership

Joseph MBA CEO and Member of Executive Committee
Joseph Jimenez CEO, Member of the Executive Committee, MBA
Daniel Vasella Chairman of the Board of Directors, Ph.D
Daniel MD Chairman and Member of Chairmans Committee

Novartis Price and Market Media

The median price of Novartis for the period between Mon, Apr 22, 2013 and Wed, May 22, 2013 is 73.76 with a coefficient of variation of 1.14. The daily time series for the period is distributed with a sample standard deviation of 0.85, arithmetic mean of 73.9, and mean deviation of 0.72. The Stock received substential amount of media coverage during this period.
Novartis         SP 500
Price Growth (%)
 
1
Healthcare Sector Snapshot Eli Lilly Novartis LLY ...04/26/2013Macroaxis: News
2
Dividend Champions For May 201305/02/2013Macroaxis: Seeking Alpha News
3
Even Pharma Good Deeds Are Criticized05/07/2013Macroaxis: Forbes News
4
Bristol Myers Squibb Co. Pharmacyclics Inc. Hedging Against ...05/21/2013Macroaxis: News

Novartis Summary

Novartis AG [NVS] is traded on New York Stock Exchange in USA. It is located in Basel, and employs 127,724 people. The company currently falls under 'Mega-Cap' category with total capitalization of 178.27 B. Novartis AG runs under Healthcare sector within Drug Manufacturers - Major industry. This company has 2.44 B outstanding shares of which 3.2 M shares are now shorted by investors with about 1.6 days to cover shorted positions.
Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare solutions worldwide. more
Past Market
Over 30
Days
8
Out Of
100
 
Chance of
Less
Than
12 %
 
Follow Novartis with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Novartis to your reader
 

Novartis Research Report

Novartis vs. Johnson

Correlation analysis and fundamentals comparison between Novartis AG and Johnson Johnson

Novartis Executives

Jonathan Symonds CFO and Member of Executive Committee
Jonathan CBE CFO and Member of Executive Committee

Novartis Directors

Andreas Planta Member of the Board of Directors
Pierre Landolt Member of the Board of Directors
Srikant Datar Member of the Board of Directors, MBA
Ann Fudge Member of the Board of Directors
Rolf Zinkernagel Member of the Board of Directors

Novartis Management

Felix Ehrat General Counsel, Member of Executive Committee and General Counsel of Novartis International Ag, Ph.D
David Epstein Member of the Executive Committee, Division Head, Pharmaceuticals, MBA
Naomi Kelman Member of the Executive Committee, Division Head, Novartis OTC, MBA
Juergen Brokatzky-Geiger Head Human Resources and Member of the Executive Committee, Ph.D
Jeffrey George Member of the Executive Committee and Division Head, Sandoz, MBA

Novartis Fundamentals

Working Capital vs Total Asset
Current Ratio vs Cash Flow from Operations
Working Capital vs Current Asset
Market Capitalization vs Cash Flow from Operations

Novartis vs Competition

Novartis vs. Johnson Johnson
Novartis vs. Pfizer Inc
Novartis vs. Sanofi
Novartis vs. Merck Co Inc
Novartis vs. GlaxoSmithKline plc
Novartis vs. BristolMyers Squibb Company
Novartis vs. AstraZeneca PLC
Novartis vs. Eli Lilly and Company
Novartis vs. Impax Laboratories Inc

Novartis May 22 2013 Opportunity Range

Downside Deviation0.6748
Information Ratio(0.21)
Maximum Drawdown3.37
Value At Risk(1.02)
Potential Upside1.22

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium